Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

PARP Inhibition Moves to Next Phase in Ovarian Cancer

April 10th 2019

Chrisann Kyi, MD, discusses the utility of PARP inhibitors in the primary treatment and maintenance settings for patients with recurrent ovarian cancer and the next steps that lie ahead.

Chemotherapy Remains Cornerstone of Recurrent Ovarian Cancer Treatment

April 9th 2019

Jason A. Konner, MD, sheds light on the current treatment landscape for patients with platinum-sensitive and platinum-resistant/recurrent ovarian cancer

Molecular Markers: From Testing to Treatment in Ovarian Cancer

April 8th 2019

Britta Weigelt, PhD, discusses germline and somatic mutations in ovarian cancer that confer potential implications on treatment decisions, as well as those that carry an added cancer risk.

Capitalizing on Integrative Immunotherapy in Ovarian Cancer

April 8th 2019

Dmitriy Zamarin, MD, PhD, discusses ongoing research regarding immunotherapy and synergistic strategies also under investigation in advanced ovarian cancer.

Frontline Approaches Fine-Tuned in Newly Diagnosed Ovarian Cancer

April 6th 2019

Paul Sabbatini, MD, clarifies where the field stands regarding the use of bevacizumab, intraperitoneal therapy, and a 3-week dosing schedule of chemotherapy versus a weekly dose-dense regimen in the frontline setting of newly diagnosed ovarian cancer.

Surgery Still Mainstay in Advanced Ovarian Cancer

April 3rd 2019

Mario M. Leitao, Jr, MD, FACOG, FACS, Leitao highlights the decision-making process for the placement of surgery in patients with newly diagnosed advanced ovarian cancer, as well as the use of hyperthermic intraperitoneal chemotherapy.

Dr. Leitao on Eligibility for Neoadjuvant Chemotherapy in Advanced Ovarian Cancer

April 2nd 2019

Mario M. Leitao Jr, MD, FACOG, FACS, fellowship director, gynecology service, director, Minimal Access and Robotic Surgery Program, Department of Surgery, Memorial Sloan Kettering Cancer Center, discusses patient eligibility for neoadjuvant chemotherapy in advanced ovarian cancer.

Dr. Cibula on Adding Dendritic Cell-Based Immunotherapy to Chemotherapy in Ovarian Cancer

March 29th 2019

David Cibula, MD, a gynecologic oncologist at the Gynaecologic Center of Charles University, discusses a trial that examined the addition of dendritic cell-based immunotherapy to chemotherapy in patients with relapsed ovarian cancer.

Dr. Essel on Repeat Use of PARP Inhibitors in Ovarian Cancer

March 29th 2019

Kathleen G. Essel, MD, gynecologic oncology fellow, Stephenson Cancer Center, University of Oklahoma, discusses repeat exposure to PARP inhibitors in the treatment of patients with ovarian cancer.

Dose Modulation Should Not Be Undervalued in Oncology

March 28th 2019

Considering the decades of clinical investigation involving cytotoxic therapy of malignant disease, it is remarkable— even disconcerting—just how little is understood about the optimal delivery of this critical cancer treatment strategy.

Dr. Coleman on Benefit of Rucaparib in Ovarian Cancer

March 28th 2019

Robert Coleman, MD, professor in the Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses the benefit of rucaparib in the treatment of patients with ovarian cancer.

Dr. Matulonis on Individualized Dosing of Niraparib in Ovarian Cancer

March 26th 2019

Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses individualized dosing of niraparib in the treatment of patients with ovarian cancer.

PARP Inhibition Strategies Refined in Ovarian Cancer Guidelines

March 24th 2019

An updated guideline (version 1.2019) from the NCCN for the management of ovarian cancer recommends specific PARP inhibitors for the treatment of recurrent disease, describes patient selection criteria for each agent, and establishes criteria for PARP inhibitor maintenance therapy.

Dr. Landen Discusses p53 Mutations in Ovarian Cancer

March 20th 2019

Chip Landen, MD, associate professor, Division of Gynecologic Oncology, University of Virginia Health System, discusses the role of p53 mutations in patients with ovarian cancer.

Phase III Avelumab Trial Discontinued in Frontline Ovarian Cancer

March 20th 2019

The ongoing phase III JAVELIN Ovarian PARP 100 study, which was evaluating the efficacy and safety of avelumab in combination with chemotherapy followed by maintenance avelumab in combination with talazoparib in patients with locally advanced or metastatic ovarian cancer, has been discontinued.

Olaparib Plus Neratinib Shows Early Potential in HER2+ Ovarian Cancer

March 19th 2019

Combination use of olaparib and neratinib may represent a novel therapeutic option for chemotherapy-resistant patients with HER2-positive, homologous recombination–proficient ovarian cancer tumors.

Adding Dendritic Cell-Based Immunotherapy to Chemo Improves OS in Relapsed Ovarian Cancer

March 19th 2019

The addition of the dendritic cell-based immunotherapy DCVAC/OvCA to standard carboplatin and gemcitabine led to a significant improvement in overall survival in patients with relapsed, platinum-sensitive, epithelial ovarian cancer.

Dr. Lu on the Challenges of Risk-Reducing Salpingo-Oophorectomy in Ovarian Cancer

March 19th 2019

Karen H. Lu, MD, professor and chair in the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center discusses the challenges of risk-reducing salpingo-oophorectomy in women with an increased risk for hereditary ovarian cancer.

Dr. Ledermann on PARP Inhibitors in Maintenance Therapy for Ovarian Cancer

March 18th 2019

Jonathan Ledermann, MD, professor of medical oncology at UCL Cancer Institute in London, discusses the growing use of PARP inhibitors in maintenance therapy for ovarian cancer in an interview during the 2019 SGO Annual Meeting.

Pembrolizumab/Bevacizumab Regimen Induces Durable Responses in Ovarian Cancer

March 18th 2019

Combination therapy with pembrolizumab, bevacizumab, and metronomic cyclophosphamide induced a 95% disease control rate and 40% overall response rate among women with recurrent ovarian cancer.